Genedata AG Release: Advanced Protein Centre of The Hospital For Sick Children Adopts Genedata Expressionist for Mass Spectrometry
"A large part of our business is cancer biomarker identification and we want to offer label-free proteomics to our research community," said Paul Taylor, manager of the Advanced Protein Centre. "We methodically researched all available options from vendor-specific to Open Source solutions and none compared to Genedata Expressionist's analytic and visualization capabilities for MS. Most other solutions are for small machines and make far too many compromises, eliminating lots of data on first-pass filtering. Being able to quantify very small signals allows us to dig deeper into the proteome, which expands the potential biomarker list. Genedata Expressionist doesn't filter out data. It analyzes all the data, easily handling tens to hundreds of 300- to 400- megabytes raw data files. Bottom line - Genedata got the math right. The underlying algorithms work in Genedata Expressionist to give us automated label-free quantitation."
Eye-opening Visualization While the Advanced Protein Centre is using Genedata Expressionist, including the new Refiner MS module for label-free quantitation, the system also addresses a range of set-ups from simple one-dimensional spectra to complex experiments involving labeled technologies in proteomics, metabolomics, and lipidomics. Genedata Expressionist features direct search engine integration from within workflows for interactive searches with Mascot (used by the Advanced Protein Center), ChemSpider, and HMDB, as well as offline import results from Mascot, SEQUEST, and MetaboCard - without information loss. Combining novel visualization for real-time interactive data quality assessment, Refiner MS uses sophisticated algorithms for intensity and alignment correction, peak detection, quantification, and matching.
"Expressionist visualization is literally eye-opening when looking at data," continued Taylor. "For example, the 3D plots tell you so much more than the histograms we are accustomed to using and the viewer creates a mega-picture of what is going on. The viewer alone has enabled better quality control, allowing us to modify and improve our methods files. We're using the Genedata solution to review data with our researchers and other proteomics facilities - it's fast and intuitive and works as a great stand-alone solution."
"Label-free proteomic experiments are not easy to analyze and the Advanced Protein Centre is successfully stretching the boundaries in biomarker research," noted Dr. Othmar Pfannes, CEO of Genedata. "We're delighted that Genedata Expressionist is contributing to this innovative work. Moreover, the Centre's adoption of the Genedata Expressionist system validates how Genedata solutions integrate advanced algorithms that align with and support our customer's specific business processes and workflows."
About Genedata
Genedata transforms data into intelligence with a portfolio of advanced software solutions for drug discovery and life science research, which spans target, lead and biomarker discovery. Used by a majority of the world's top 50 pharmaceutical companies and leading research organizations, Genedata Phylosopher®, Genedata Screener®, Genedata Expressionist®, Genedata Analyst™, and Genedata Selector™ make research data accessible and understandable, enabling scientific discovery that fights disease and improves health worldwide. Founded in 1997, Genedata is privately held, with offices in Switzerland, Germany, Japan and the US. www.genedata.com
Contacts Allison Kurz Genedata Marketing & Communications Phone: +41 61 511 8459 communications@genedata.com
Jackie Thrasivoulos Genedata Public Relations Phone: +1 508 881 3109 jackie.thrasivoulos@genedata.com
Disclaimer The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
All product and service names mentioned are the trademarks of their respective companies.